269 related articles for article (PubMed ID: 24412300)
1. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.
Streng A; Liese JG
Vaccine; 2014 Feb; 32(8):897-900. PubMed ID: 24412300
[TBL] [Abstract][Full Text] [Related]
2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
4. Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study.
Sanftenberg L; Schrörs HJ; Schelling J
Vaccine; 2016 Jul; 34(34):3938-41. PubMed ID: 27318420
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
7. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
Schink T; Holstiege J; Kowalzik F; Zepp F; Garbe E
Vaccine; 2014 Feb; 32(6):645-50. PubMed ID: 24374498
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
[TBL] [Abstract][Full Text] [Related]
10. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
Bauchau V; Van Holle L; Cohen C
Drug Saf; 2015 Nov; 38(11):1095-102. PubMed ID: 26251259
[TBL] [Abstract][Full Text] [Related]
11. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
Casabona G; Berton O; Singh T; Knuf M; Bonanni P
Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
[TBL] [Abstract][Full Text] [Related]
12. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
13. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
Committee on Infectious Diseases
Pediatrics; 2011 Sep; 128(3):630-2. PubMed ID: 21873692
[TBL] [Abstract][Full Text] [Related]
14. Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers.
Ackerson BK; Li BH; Sy LS; Cheetham TC; Jacobsen SJ
Vaccine; 2014 Apr; 32(16):1863-8. PubMed ID: 24508041
[TBL] [Abstract][Full Text] [Related]
15. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
18. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
